The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors
Jonathan R Strosberg, Thorvardur R Halfdanarson, Andrew M Bellizzi, Jennifer A Chan, Joseph S Dillon, Anthony P Heaney, Pamela L Kunz, Thomas M O'Dorisio, Riad Salem, Eva Segelov, James R Howe, Rodney F Pommier, Kari Brendtro, Mohammad A Bashir, Simron Singh, Michael C Soulen, Laura Tang, Jerome S Zacks, James C Yao, Emily K Bergsland, Jonathan R Strosberg, Thorvardur R Halfdanarson, Andrew M Bellizzi, Jennifer A Chan, Joseph S Dillon, Anthony P Heaney, Pamela L Kunz, Thomas M O'Dorisio, Riad Salem, Eva Segelov, James R Howe, Rodney F Pommier, Kari Brendtro, Mohammad A Bashir, Simron Singh, Michael C Soulen, Laura Tang, Jerome S Zacks, James C Yao, Emily K Bergsland
Abstract
There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patients with refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut). Based on these and other advances, the North American Neuroendocrine Tumor Society convened a multidisciplinary panel of experts with the goal of updating consensus-based guidelines for evaluation and treatment of midgut NETs. The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article. Surgical guidelines are described in a companion article.
Source: PubMed